Aligos Therapeutics Inc
(ALGS)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
by (Cboe BZX)
[[ item.lastPrice ]]
[[ item.priceChange ]]
([[ item.percentChange ]])
[[ item.tradeTime ]]
[NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]]
[[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]]
[[ item.lastPriceExt ]]
[[ item.priceChangeExt ]]
([[ item.percentChangeExt ]])
[[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 09-2020 | 06-2020 | 03-2020 | 12-2019 | 12-2018 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -74,123 | -40,826 | -20,029 | -52,264 | 0 |
| Depreciation Amortization | 2,623 | 1,647 | 465 | 1,422 | 0 |
| Accounts payable and accrued liabilities | 5,552 | 1,972 | -121 | N/A | N/A |
| Other Working Capital | 3,564 | 816 | -1,175 | 3,671 | 0 |
| Other Operating Activity | 7,805 | -1,622 | 541 | 404 | 0 |
| Operating Cash Flow | $-54,579 | $-38,013 | $-20,319 | $-46,767 | $0 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -2,179 | -27,096 | -9,496 | N/A | N/A |
| PPE Investments | -2,003 | -1,659 | -1,090 | -2,786 | 0 |
| Purchase Of Investment | N/A | -13,183 | -13,183 | N/A | N/A |
| Sale Of Investment | 22,000 | 33,100 | N/A | N/A | N/A |
| Other Investing Activity | 0 | 0 | 0 | 9,577 | 0 |
| Investing Cash Flow | $17,818 | $-8,838 | $-23,769 | $6,791 | $0 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -46 | -28 | -11 | N/A | N/A |
| Common Stock Issued | 197 | 62 | 368 | N/A | N/A |
| Other Financing Activity | -1,121 | -55 | -405 | 85,532 | 0 |
| Financing Cash Flow | $-970 | $-21 | $-48 | $85,532 | $0 |
| Beginning Cash Position | 70,103 | 70,103 | 70,103 | 24,547 | 0 |
| End Cash Position | 32,372 | 23,231 | 25,967 | 70,103 | 0 |
| Net Cash Flow | $-37,731 | $-46,872 | $-44,136 | $45,556 | $0 |
| Free Cash Flow | |||||
| Operating Cash Flow | -54,579 | -38,013 | -20,319 | -46,767 | 0 |
| Capital Expenditure | -2,003 | -1,659 | -1,090 | N/A | N/A |
| Free Cash Flow | -56,582 | -39,672 | -21,409 | -46,767 | 0 |